People · Operator
Named in public records as an officer, director or promoter · active 2008–2025 · Other Health Care, Biotechnology, Biotech / Pharma, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Endotronix Inc | — | Other Health Care | Series C | $116.1M | $1.6B | 2016 |
| Verax Biomedical Inc | — | Biotechnology | Series A | $45.8M | $91.8M | 2009 |
| General Fluidics Corp | — | Other Health Care | Series B | $34.6M | $119.3M | 2024 |
| Brainbox Solutions, Inc. | — | Biotechnology | Series B | $26.0M | $67.7M | 2020 |
| Cerebral Inc. | — | Other Health Care | Series B | $25.0M | $117.3M | 2025 |
| Hydrocision Inc | — | Biotechnology | Seed | $9.2M | $10.0M | 2008 |
| Oncoheroes Biosciences Inc. | — | Biotech / Pharma | Series A | $8.9M | $296.5M | 2018 |
| Claros Diagnostics Inc | — | Other | Seed | $4.0M | $74.4M | 2009 |
| Spirus Medical Inc | — | Other Health Care | Pre-Seed | $841K | $6.4M | 2009 |
Marc Goldberg at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Marc Goldberg on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| ROBERT ZIESERL | 2 | 5 |
| MARC E. GOLDBERG | 2 | 4 |
| Jeffrey T Barnes | 2 | 3 |
| PAUL LAVIOLETTE | 1 | 12 |
| Buzz Benson | 1 | 8 |
| Fouad Azzam | 1 | 8 |
| Dennis Costello | 1 | 6 |
| Gerry Brunk | 1 | 5 |
| Caroline Popper | 1 | 5 |
| Doug Wall | 1 | 4 |
| John Flavin | 1 | 4 |
| Robert Flanagan | 1 | 4 |
| JOE DEL GUERCIO | 1 | 4 |
| Sujuan Ba | 1 | 3 |
| Keith Greenfield | 1 | 3 |
| James Lousararian | 1 | 3 |
| Terry Wall | 1 | 3 |
| John C Miller | 1 | 3 |
| Thomas D. Abert | 1 | 3 |
| Scott Gazelle | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.